Program
monalizumab
Also written as “Monalizumab”, “NNC 0141-0000-0100” and “Durvalumab + Monalizumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Colonic Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell, led by 2 companies.
Drug pageMonalizumab: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 53 open or running | phase 3since Sep 23, 2020 | Dec 10, 2018 | Jan 8, 2027phase 3 · NCT05221840 |
| Innate Pharmaits history only | 40 open or running | phase 2since Jan 2, 2015 | May 31, 2011 | none ahead |
- Named in AstraZeneca’s own pipeline as
monalizumab
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseAstraZeneca licensed it from Innate Pharma, for full rights in cancer, under their 2015 co-development agreement.Announced Oct 23, 2018 · Source: AstraZeneca, Oct 23, 2018
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named monalizumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, NNC 0141-0000-0100
- Oct 23, 2018AstraZeneca licensed it from Innate PharmaLicenseFull rights in cancer, under their 2015 co-development agreement · announced · AstraZeneca
- Dec 10, 2018First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03822351 · 189 enrolled · United States, Canada, France and more
- Oct 16, 2019Phase 2 study in Colonic NeoplasmsNCT04145193
- Sep 23, 2020Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT04590963 · 370 enrolled · United States, Argentina, Australia and more
- Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550 · 630 planned · United States, Belgium, Canada and more
- Jan 14, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840 · 1,051 enrolled · United States, Australia, Brazil and more
- Nov 4, 2026Primary completion moved from 2026-09-30 to 2027-01-08Date moved laterphase 3 · +3 months · NCT05221840
Ahead
- Jan 8, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840
- May 28, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550
TargetBeta
“A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prev…”NCIt, read by Claude
Other programs on KLRC1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628rule | Exelixis | phase 1 | 1 |
Studies
All 5 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05221840Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jan 8, 2027 | 1,051 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | May 28, 2030 | 630 |
| NCT04590963Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 11, 2022 | 370 |
| NCT04145193Colonic Neoplasms | 2 | Withdrawn | Mar 19, 2024 | 0 |
| NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | Jul 18, 2023 | 189 |
How it is read
Names in the registry
- “Monalizumab”, 4 entries
- “NNC 0141-0000-0100”, 3 entries
- “Durvalumab + Monalizumab”, 1 entry
- “E3 - mFOLFOX6, durvalumab and monalizumab”, 1 entry
- “monalizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Head and Neck Neoplasms, 1 study
- Colonic Neoplasms, 1 study
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.